News

Mentia is honored to be selected for the inaugural Artificial Intelligence and Technology Collaboratory #A2Collective #johnshopkinsuniversity The National Institutes of Health Full story at https://lnkd.in/g6ewtb9W

There are now more Americans aged 65 and older than at any other point in history, and that number is expected to rise, according to the National Institute on Aging (NIA). With longer lifespans come challenges like Alzheimer’s, which about one in nine Americans aged 65 or older have.

The a2 Pilot Awards were created to encourage the development of tech for the elderly. Funded by the NIA with $40 million over the next five years, the awards announced today the first cohort of 33 projects selected for funding. The majority use artificial intelligence or machine learning tech, and 40% are led by women.

Deployed military personnel frequently face numerous health and safety hazards as part of their daily activities in service to their nation. Among many dangers is the possibility of encountering hemorrhagic fever viruses (HFVs), a group of highly infectious pathogens such as the Ebola virus. Many of these diseases do not currently have effective therapeutics and can be prevalent in areas where service members are deployed, putting them at risk of exposure.

George Mason University infectious disease researcher Aarthi Narayanan has partnered with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and Cyclica, a biotechnology company based in Canada, to identify potential broad-spectrum therapeutics for illnesses triggered by HFVs and similar pathogens.

Biopharmaceutical company Kite Pharma will expand its footprint in Frederick County with a new warehouse that will bring 100 new jobs to the area, the company announced Tuesday.

Kite, a Los Angeles-based subsidiary of Gilead Sciences (NASDAQ: GILD), will build an approximately 70,000-square-foot raw materials warehouse to support its global cell therapy manufacturing network. The company’s CAR T-cell therapy uses a person’s own immune system to recognize, attack and destroy certain types of cancer with a one-time, individualized treatment.

Today, College Park, Maryland quantum leader IonQ announced its first-ever acquisition.

The DMV company acquired the operating assets of Entangled Networks, a Toronto, Canada-based startup founded in 2021. Entangled Networks specialized in enabling computing for multiple quantum processors, including those that are distributed. Through the deal, the Entangled team will become the staff of IonQ Canada, the quantum pioneer’s first outpost in the country.

Image: IonQ’s Kai Hudek in the lab. (Courtesy photo)

To kick off the new year, The Galien Foundation is delighted to share with you highlights from the 2022 Prix Galien Awards Ceremony and recognize the incredible achievements of the Medalists  of the Prix Galien Golden Jubilee and the Prix Galien USA.

Kite , a global biopharmaceutical company, is adding 100 new jobs and expanding its cell therapy manufacturing operations in Frederick County.

A Gilead company, Kite is planning to construct a 70,000 square-foot warehouse adjacent to its current facility in the Urbana Corporate Center, which will help expand its global manufacturing network. The company originally announced its entry into Maryland back in 2019 , helping form the largest dedicated in-house cell therapy manufacturing network in the world. The company expects to employ more than 500 full-time staff between its two facilities by the end of 2026.

Linshom Medical raising $3M series A to launch respiratory monitor

Ellicott City startup Linshom Medical is looking to raise a $3 million round as it works to develop a medical device that catches the warning signs of a respiratory crisis.

CEO Richard Hughen plans to use the series A raise, as well as a $2.4 million grant from the National Institutes of Health, to fund a study to prove the company’s respiratory monitor is effective at detecting breathing issues. The company previously raised $1.5 million in convertible notes. Linshom has raised $1 million of its $3 million series A goal so far, with support from the Maryland Momentum Fund, the Maryland Technology Development Corp. and other investors.

Once the studies are complete, the three-person company is planning to do a soft launch in a few hospital systems late this year.

· Global biopharmaceutical company focusing on metabolic and digestive diseases

· Proceeds to fund clinical and business development

ROCKVILLE, MD and SHENZHEN, CHINA,January 5, 2023— HighTide Therapeutics Inc. (“HighTide”), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the closing of a $107 million Series C/C+ financing led by the TCM Healthcare Fund of Guangdong, managed by China Development Bank Capital. Other investors included Yuexiu Fund and Yuthai Fund.

On September 30, 2022, the SBIR and STTR Extension Act of 2022 (the Act) was enacted, reauthorizing the SBIR and STTR programs until September 30, 2025. The Act makes several significant changes related to national security risks and foreign influence in the programs. The changes include agency implementation of due diligence procedures, new offeror disclosure and ongoing contractor reporting requirements, and new award eligibility requirements, with an offeror’s or contractor’s omissions or misstatements resulting in repayment of the entire award amount, among other changes to the programs.